scholarly journals Soft tissue sarcoma across the age spectrum: A population-based study from the surveillance epidemiology and end results database

2011 ◽  
Vol 57 (6) ◽  
pp. 943-949 ◽  
Author(s):  
Andrea Ferrari ◽  
Iyad Sultan ◽  
Tseng Tien Huang ◽  
Carlos Rodriguez-Galindo ◽  
Ahmad Shehadeh ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Population Based ◽  
Population Based Study ◽  
End Results

Rates of survival throughout the years in soft tissue sarcoma with synchronous metastases: Results of a population-based study.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 11068-11068
Author(s):  
Melissa Vos ◽  
Vincent K.Y. Ho ◽  
Astrid W. Oosten ◽  
Cornelis Verhoef ◽  
Stefan Sleijfer
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
The Netherlands ◽  
Population Based ◽  
Favorable Effect ◽  
Adult Type ◽  
Population Based Study ◽  
Primary Tumor Site ◽  
Synchronous Metastases

11068 Background: Roughly 10% of patients with soft tissue sarcoma (STS) present with synchronous metastases and generally cannot be cured anymore. With the registration of trabectedin, pazopanib and the identification of other agents exerting activity against STS, the treatment of these patients in the Netherlands has changed considerably in the last decade. The aim of this population-based study is to examine whether the overall survival (OS) of patients with STS and synchronous metastases has improved over the years. Methods: All patients diagnosed with adult-type STS and synchronous metastases between 1989 and 2014 were queried from the Netherlands Cancer Registry. Trends in OS were assessed by the Kaplan Meier method and log rank test in different timeframes based on year of registration of trabectedin ( < 2007 vs. ≥2007) and pazopanib ( < 2012 vs. ≥2012). A multivariable Cox regression analysis was performed to identify relevant characteristics prognostic for OS. Results: In total, 1,393 patients with adult-type STS and synchronous metastases were identified. Over the whole time period, median OS did not improve significantly (5.8 months in 1989-1994 to 8.1 months in 2010-2014, p = 0.095), but median OS < 2007 compared to ≥2007 did improve significantly (5.8 months to 7.3 months, p = 0.035). This was particularly apparent in the liposarcoma subgroup, where median OS doubled (5.2 months to 11.5 months, p = 0.020). Median OS < 2012 compared to ≥2012 did not increase significantly (6.1 months to 7.6 months, p = 0.062), though there was a relatively short follow-up of 2 years while the survival curve seems to reach a plateau phase. Aside from not receiving (any type of) treatment, elderly age, STS subtype other than lipo- or leiomyosarcoma, high or unknown grade and nodal involvement were significant negative predictors for OS, whereas primary tumor site in the extremity and surgery in an academic center had a favorable effect on OS. Conclusions: OS of STS patients with synchronous metastases has not improved significantly over the years, except for the subgroup of liposarcomas after 2007. A longer follow-up period is needed to clarify the impact of pazopanib on OS in patients with metastatic STS.

Soft tissue sarcoma after treatment for breast cancer—A Swedish population-based study

1998 ◽  
Vol 34 (13) ◽  
pp. 2068-2075 ◽  
Author(s):  
P. Karlsson ◽  
E. Holmberg ◽  
A. Samuelsson ◽  
K.-A. Johansson ◽  
A. Wallgren
Keyword(s):  
Breast Cancer ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Population Based ◽  
Swedish Population ◽  
Population Based Study

scholarly journals Increased risk of malignancies in a population-based study of 818 soft-tissue sarcoma patients

2006 ◽  
Vol 95 (8) ◽  
pp. 986-990 ◽  
Author(s):  
J Fernebro ◽  
A Bladström ◽  
A Rydholm ◽  
P Gustafson ◽  
H Olsson ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Population Based ◽  
Population Based Study ◽  
Increased Risk

scholarly journals Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: a French prospective population-based study

2014 ◽  
Vol 25 (1) ◽  
pp. 225-231 ◽  
Author(s):  
S. Mathoulin-Pélissier ◽  
C. Chevreau ◽  
C. Bellera ◽  
E. Bauvin ◽  
M. Savès ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Treatment Guidelines ◽  
Population Based ◽  
Diagnosis And Treatment ◽  
Population Based Study

Improved diagnosis and treatment of soft tissue sarcoma patients after implementation of national guidelines: A population-based study

2009 ◽  
Vol 35 (12) ◽  
pp. 1326-1332 ◽  
Author(s):  
M.L.E.A. Jansen-Landheer ◽  
P. Krijnen ◽  
M.J. Oostindiër ◽  
W.M. Kloosterman-Boele ◽  
E.M. Noordijk ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Population Based ◽  
Diagnosis And Treatment ◽  
National Guidelines ◽  
Population Based Study

Chemotherapy Use in Elderly Patients with Soft Tissue Sarcoma: A Population-based Study

2013 ◽  
Vol 31 (2) ◽  
pp. 83-91 ◽  
Author(s):  
Igor Matushansky ◽  
Filemon Dela Cruz ◽  
Beverly J. Insel ◽  
Dawn L. Hershman ◽  
Alfred I. Neugut
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Elderly Patients ◽  
Population Based ◽  
Population Based Study

A population-based study of soft tissue sarcoma incidence and survival in Australia: An analysis of 26,970 cases

2019 ◽  
Vol 63 ◽  
pp. 101590 ◽  
Author(s):  
Taryn Bessen ◽  
Gillian E Caughey ◽  
Sepehr Shakib ◽  
J. Alexa Potter ◽  
Jessica Reid ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Population Based ◽  
Population Based Study

Incidence of soft tissue sarcoma in Taiwan: A nationwide population-based study (2007–2013)

2019 ◽  
Vol 60 ◽  
pp. 185-192
Author(s):  
Giun-Yi Hung ◽  
Jiun-Lin Horng ◽  
Paul Chih-Hsueh Chen ◽  
Li-Yih Lin ◽  
Jinn-Yang Chen ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Population Based ◽  
Population Based Study
Sign in / Sign up

Export Citation Format

Share Document